These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 25498454)

  • 1. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.
    McMullen JR; Boey EJ; Ooi JY; Seymour JF; Keating MJ; Tam CS
    Blood; 2014 Dec; 124(25):3829-30. PubMed ID: 25498454
    [No Abstract]   [Full Text] [Related]  

  • 2. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib.
    Byrd JC; Hillmen P; James DF
    Blood; 2015 Mar; 125(10):1673. PubMed ID: 25745185
    [No Abstract]   [Full Text] [Related]  

  • 4. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis.
    Leong DP; Caron F; Hillis C; Duan A; Healey JS; Fraser G; Siegal D
    Blood; 2016 Jul; 128(1):138-40. PubMed ID: 27247135
    [No Abstract]   [Full Text] [Related]  

  • 5. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
    Brown JR
    Leuk Lymphoma; 2014 Feb; 55(2):263-9. PubMed ID: 23656200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targets for Ibrutinib Beyond B Cell Malignancies.
    Berglöf A; Hamasy A; Meinke S; Palma M; Krstic A; Månsson R; Kimby E; Österborg A; Smith CI
    Scand J Immunol; 2015 Sep; 82(3):208-17. PubMed ID: 26111359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ibrutinib prescription in B-cell lymphoid neoplasms].
    Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
    Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
    Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
    Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
    Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New approved indication for ibrutinib.
    Aschenbrenner DS
    Am J Nurs; 2014 Jun; 114(6):21. PubMed ID: 24869579
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
    Reda G; Fattizzo B; Cassin R; Mattiello V; Tonella T; Giannarelli D; Massari F; Cortelezzi A
    J Hematol Oncol; 2018 Jun; 11(1):79. PubMed ID: 29891001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).
    Burger JA; Buggy JJ
    Leuk Lymphoma; 2013 Nov; 54(11):2385-91. PubMed ID: 23425038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib (Imbruvica). Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival.
    January
    Prescrire Int; 2016 Apr; 25(170):89-92. PubMed ID: 27183765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ibrutinib: A new drug of B-cell malignancies].
    Thieblemont C
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.
    Spaargaren M; de Rooij MF; Kater AP; Eldering E
    Oncogene; 2015 May; 34(19):2426-36. PubMed ID: 24954503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib treatment of CLL: the cancer fights back.
    Young RM; Staudt LM
    Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B cell receptor inhibition as a target for CLL therapy.
    Jeyakumar D; O'Brien S
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):2-14. PubMed ID: 27742069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.
    Zhao X; Bodo J; Sun D; Durkin L; Lin J; Smith MR; Hsi ED
    Br J Haematol; 2015 Mar; 168(5):765-8. PubMed ID: 25284608
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.